BACKGROUND: Day 5 serum inhibin B during IVF treatment has been investigated as a predictor of outcome. METHODS: A total of 54 women (≤39 years, normal menses and endocrine profiles) were treated with urinary gonadotrophins or recombinant FSH following pituitary down-regulation. Serum day 3 FSH in a preceding cycle was <8.5 IU/l. Plasma inhibin B, inhibin A and estradiol were determined after 4 days of gonadotrophin administration (day 5). RESULTS: Day 5 inhibin B was the most highly correlated with the number of mature follicles (>14 mm), oocytes retrieved and fertilized. Receiver operating characteristic analysis gave high accuracy for day 5 inhibin B in predicting ovarian response and indicated that a threshold of 400 pg/ml may be helpful in the decision as to whether to continue treatment. Women with <400 pg/ml (n ⍧ 16) had lower numbers of follicles, mature follicles, oocytes retrieved, fertilized and cleaved compared with those >400 pg/ml (n ⍧ 36) and this threshold gave a positive likelihood ratio of 30, 92.9% sensitivity, 95.0% specificity and 86.7% positive predictive value to detect poor ovarian response. Day 5 inhibin B was the best predictor of pregnancy (no live births and four cycles cancelled, low inhibin group; nine live births and no cancelled cycles, high inhibin group). CONCLUSIONS: Normogonadotrophic, normogonadal women with day 5 inhibin B <400 pg/ml in down-regulated cycles have a poor response to ovarian stimulation and are less likely to conceive compared with women with higher day 5 inhibin B.
Introduction
Several approaches have been used to predict ovarian reserve and IVF outcome in response to gonadotrophin stimulation. For example, the measurement of day 3 FSH in the preceding normal cycle (Scott et al., 1989; Cahill et al., 1994; Scott and Hofman, 1995; Fawzy et al., 1997; Sharara et al., 1998) , follicular blood flow (Nargund et al., 1996a; Van Blerkom et al., 1997; Chui et al., 1997; Engmann et al., 1999) , ovarian volume (Syrop et al., 1995 (Syrop et al., , 1999 Lass et al., 1997) or pretreatment transvaginal ultrasound of the antral follicles (Tomàs et al., 1997; Chang et al., 1998) have all been investigated. Of these, the day 3 basal FSH levels has proved the most useful, in that a poorer IVF outcome was associated with higher levels of the hormone even within the normal range (Fawzy et al., 1997) , and these results are in broad agreement with those reported by previous investigators (Cahill et al., 1994; Seifer et al., 1997; Peñarrubia et al., 2000) .
With respect to inhibin, early reports indicated that this family of hormones may have potential as a marker of follicular development and numbers due to its production being FSH dependent (McLachlan et al., 1986; Hughes et al., 1990; Matson et al., 1991; Buckler et al., 1992; Burger, 1993; Mitchell et al., 1996) . However, most of these studies were complicated by specificity problems associated with the radioimmunoassay used at that time. With the help of the new specific enzyme-linked immunoassays it became possible to measure the different species of inhibin (Groome et al., 1994 (Groome et al., , 1995 and it is now clear that inhibin B rises in the early follicular phase of both unstimulated and FSH-stimulated cycles (Lockwood et al., 1996; Fawzy et al., 2001 ) and can be used as a direct measure of ovarian follicular reserve (Seifer et al., 1997) . Furthermore, changes in the serum inhibin B levels may precede those found in basal FSH levels as ovarian reserve declines (Siefer et al., 1999) . With regard to the value of basal day 3 inhibin levels, the early study of Siefer et al. indicated that day 3 inhibin B levels were predictive of IVF outcome (Siefer et al., 1997) . However, several recent studies failed to find clinical value in measuring basal inhibin B with regard to IVF outcome (Corson et al., 1999; Hall et al., 1999; Ravhon et al., 2000) .
Furthermore, on their own, normal baseline values are not a guarantee that an endocrine organ is functioning normally (Wallach, 1995) in that patients with normal baseline measurements may also have compromised ovarian reserve (Farhi et al., 1997; Kim et al., 1998) . A clearer picture of the likely ability of the ovary to respond, and what hormone markers are of value in predicting this reserve, may only become evident during gonadotrophin treatment itself, and a number of studies have been designed to address this. For example, a recent retrospective study found that day 5 inhibin B levels in treatment cycles correlated well with the lack of an ovarian response but not to pregnancy. Further, a multicentre study on the efficacy of a daily fixed dose stimulation regimen of 100 or 200 IU recombinant FSH (Eldar-Geva et al., 2000) showed that the rise in serum inhibin B levels after 4-10 days of FSH treatment was correlated with the number of recruited follicles and oocytes retrieved.
To date, to our knowledge, there has not been a prospective study primarily designed to investigate the predictive value of serum inhibin B at the early follicular phase of an IVF cycle in comparison with other hormones. The need for such studies has been stressed (Galtier-Dereure et al., 1996; Fabregues et al., 2000) . To that end, we have performed a prospective assessor-blind controlled trial on 54 women to evaluate the value of measuring the levels of early follicular phase (day 5) inhibin B, inhibin A and estradiol in predicting IVF outcome in terms of ovarian response and pregnancy.
Materials and methods

Subjects and study design
Women presenting with unexplained or tubal infertility at the Human Assisted Reproduction Unit in Ireland (HARI), Rotunda Hospital, Dublin were recruited to take part in this study. Ethical Committee approval and specific consent to participate in the study were obtained.
The study was prospective, controlled and assessor-blind. The inclusion criteria were female age at the time of screening (20-39 years), body mass index (BMI, 20-28 kg/m 2 ), ജ2 years duration of infertility with a full fertility profile (Harrison et al., 1981) , a normal menstrual cycle (range 24-35 days), no previous attempts at any kind of assisted conception techniques, the presence of two ovaries, no previous ovarian surgery and a normal day 3 FSH (Ͻ8.5 IU/l) (Fawzy et al., 1997) measured in a preceding cycle. The exclusion criteria were endocrine abnormalities including hyperprolactinaemia and polycystic ovarian syndrome (PCOS), and previous exposure to gonadotrophin treatment. Those women with male partners having a total sperm concentration Ͻ20ϫ10 6 /ml, with sperm motility and normal morphology Ͻ40% (World Health Organization, 1992), were also excluded from the study.
A total of 54 women were randomized to receive 225 IU/day of either urinary gonadotrophins in the form of Humegon (n ϭ 13; Organon Laboratories Ltd, Cambridge, UK), Normegon (n ϭ 11; Organon), Orgafol (n ⍧ 14; Organon) or recombinant FSH (n ϭ 16; Puregon, Organon; and Gonal-F; Serono Laboratories Ltd, Welwyn, Herts, UK) in their first IVF cycle. The randomization of gonadotrophins used was done by the pharmacist using a computerized code and was blind to the clinician. The urinary gonadotrophin preparations were from a single batch for each drug and all the gonadotrophic injections were administered i.m. by the clinic nurses. This was not a double-blind study because the gonadotrophin preparations differed in appearance. However, all the gonadotrophin drugs were administered i.m. by the nursing staff independent of the clinician's activities in evaluating the scans and making the clinical decisions. Concealment of treatment allocation avoided any bias towards cycle cancellation or changing the dose of specific drug during the treatment. This also ensured patient compliance with regard to drug administration. Despite the fact that diagnostic test studies require a cohort design, the assessor-blind randomization between the four gonadotrophins avoided potential bias. In IVF clinics, usually a mixture of drugs is available to the clinician (Fawzy and Harrison, 1995) and a predictive test for IVF outcomes should not be influenced by the kind of drug administered. In addition we found no difference in the number of follicles stimulated by the four different preparations used (Table I) . Furthermore, no differences were found in the concentration of inhibin B, inhibin A and estradiol per follicle (ജ14 mm) on day 5 or pregnancy rate for the four drugs administered (Table II) .
Following screening by vaginal ultrasound on day 1 of the menstrual cycle, patients were placed on a long protocol down-regulation regime (Kondaveeti- Gordon et al., 1996) . Buserelin (Superfact; Hoechst, Uxbridge, UK) administered as a nasal spray, 150 µg 6 hourly, was used for pituitary down-regulation. An initial check for downregulation was made at 14 days and then if necessary rechecked until serum estradiol was ഛ100 pmol/l with quiescent ovaries on ultrasound scan (no cysts ജ10 mm). IVF treatment was performed as described previously (Harrison et al., 1992 Gordon et al., 2001) .
Ovarian follicles were measured by 5 MHz vaginal transducer attached to a sector scanner (RT3600; General Electric, Milwaukee, WI, USA) and the mean of the two largest perpendicular diameters was taken. Cycles were cancelled if the ovarian response was poor with Ͻ3 follicles at day 8 of the cycle. No cycle was cancelled in this study because of excessive response. Maturity of oocytes was based on published criteria (Veeck et al., 1983) and mature oocytes (metaphase II) had a generous expansion of cumulus-corona and a distinct polar body. Pregnancy was diagnosed by increasing concentrations of β-HCG 14 days post embryo transfer and the subsequent demonstration of an intrauterine gestational sac by transvaginal scan 2 weeks later. The pregnancy rate is defined as the clinical pregnancy per initiated cycle and birth rate was defined as the percentage of liveborn infants per initiated cycle.
No differences were observed in the ovarian response or pregnancy rate to urinary or recombinant gonadotrophins. Therefore for the purpose of this study the data were combined into a single group (n ϭ 54 cases).
Hormone assays
Blood samples were taken to examine the secretory profiles of immunoactive inhibin B, inhibin A, estradiol (E 2 ) and FSH. Days chosen for the study, according to the clinic's policy, were prior to down-regulation (pre-treatment), the day of down-regulation (day 1), the day of the first clinic visit to monitor the ovarian stimulation (day 5) after 4 days of gonadotrophin administration, and then on day 8 of the treatment cycle. The samples were taken 24 h post gonadotrophin injection and prior to the next injection. The blood samples were allowed to clot, and the serum was separated and stored at -40°C until hormone assay .
Inhibin A was measured by enzyme-linked immunosorbent assay (ELISA) using a commercial kit (Serotech, Kidlington, Oxford, UK). The assay has minimal cross-reaction with inhibin B, pro-αC or activins. The limit of detection is 4 pg/ml and intra-and inter-assay coefficient of variation (CV) was Ͻ6 and Ͻ16% over the working range 4-500 pg/ml.
Inhibin B was measured by ELISA using a commercial kit (Serotech). The assay has minimal cross-reaction with Data are presented as mean Ϯ SD (95% confidence interval). F ratio: the ratio of the variable mean squared to the error mean square. rFSH ϭ recombinant FSH; ANOVA ϭ analysis of variance; NS ϭ not significant. inhibin pro-αC or activins, and~1% cross-reaction with inhibin A. The limit of detection is 16 pg/ml and intra-and inter-assay CV was Ͻ6% and Ͻ13% over the working range of 16-1000 pg/ml. Serum estradiol was measured by Delfia kit (Wallace, Milton Keynes, Bucks, UK) according to the manufacturer's protocol. The assay has a limit of detection of 50 pmol/l and intra-and inter-assay CV of Ͻ10% and Ͻ13% over the range 100-1200 pmol/l. Serum samples were assayed for FSH using the Delfia timeresolved fluorescence immunoassay kit following the manufacturer's instructions. The limit of detection of the assay was 1 IU/l and the intra-and inter-assay CV was Ͻ6% and Ͻ13% over the range 1-250 IU/l.
Statistics and diagnostic probability testing
The data are presented as the mean and range and 95% confidence interval (CI) where appropriate. Unpaired two-tailed Student's t-test was used to compare normally distributed continuous variables and Fisher's exact test was used to compare categorical outcomes; analysis of variance was used to compare multiple variables. Correlation coefficients given are Spearman's or Pearson's, dependent on the distribution. P Ͻ 0.05 was considered to be significant.
Ovarian outcomes are presented as discrete counts and the clinical pregnancy as dichotomous (yes versus no) data. In order to make the analyses consistent for the main outcome, the number of mature oocytes was transformed into dichotomized data (yes or no). The threshold to delineate poor ovarian responders was chosen arbitrarily as 8 mature oocytes, the 25th percentile of the observed distribution of this variable, i.e. less than 8 mature oocytes (ϭ yes) or Ͼ8 (ϭ no).
A multiple regression and multiple logistic regression model was then used for all possible prognostic variables (hormones) to evaluate the relationship between different hormone concentrations and ovarian 1537 response. Age and duration of infertility were included in the regression models.
The diagnostic accuracy of different hormones (tests), described as their ability to discriminate between patients with a poor or normal ovarian response and non-pregnant and pregnant patients, was assessed by the area under the receiver operating characteristic (ROC) curve (Beck and Schultz, 1986; Zweig and Campbell, 1993) . ROC plots sensitivity (true positives) for a given concentration of the hormone (y-axis) against 1 -specificity (false positives, x-axis). The area under the ROC (AUC ROC ) is determined statistically using the Wilcoxon and Mann-Whitney U-statistics (Hanley and McNeil, 1982) . AUC ROC is a quantitative measure of accuracy of the test, where the closer the plot is to the upper left corner the higher the overall accuracy of the test variable (45°line from the lower left corner to the upper right corner; no discrimination line indicating random chance or no predictive ability). The sensitivity, specificity and positive predictive value (Chard and Lilford, 1991) were calculated at the discriminating cut-off point for the prevalence of the study population. Sensitivity is the percentage of the abnormal cases (poor ovarian response or pregnancy) correctly identified as such by the diagnostic test (i.e. true positives). Specificity is the percentage of the normal cases (normal ovarian response or non-pregnancy) correctly identified as such by the diagnostic test (i.e. false positives). The positive predictive value is calculated from the ROC analysis by plotting the percentage of true positives against the percentage of false positives at the best discriminating cut-off. The positive likelihood ratio is the ratio between the probability of a positive result given the presence of a poor ovarian response and the probability of a positive test result given the absence of a poor ovarian response.
Statistical analyses were performed on GraphPad InStat version 3.0 (San Diego, CA, USA), MedCalc version 6.0 (Mariakarke, Belgium) and Analyse-it version 1.61 for Microsoft Excel. Table III shows the clinical characteristics of the patients (n ϭ 54). Four cycles (7.4%) were cancelled because of poor ovarian response (less than 3 follicles Ͻ10 mm in diameter at day 5 or 8), two cases had no fertilization of their retrieved oocytes and two cases had no available embryos (no cleavage). In the rest of the cases, 1-3 embryos were transferred back to the uterus. There were in total 10 pregnancies (18.5% per cycle). Two ended in miscarriages (6 and 13 weeks gestation); there were seven singletons and one twin delivery. In this study, no women were admitted to the hospital because of severe ovarian hyperstimulation syndrome (OHSS) (Golan et al., 1989) ; however, six patients had mild/moderate OHSS (more than 20 oocytes, range 22-27).
Results
Hormone levels during treatment
The mean level of inhibin B rose~20-fold from day 1 (36 pg/ml, 95% CI: 28-45) to day 5 (747 pg/ml, 95% CI: 598-895). Similarly, the mean inhibin A concentration increased 14-fold from day 1 (10 pg/ml, 95% CI: 7-13) to day 5 (141 pg/ml, 95% CI: 101-181) whilst the E 2 concentration at day 5 (597 pmol/l, 95% CI: 474-720) was 8.6-fold that of its concentration at day 1 (69 pmol/l, 95% CI: 62-76). Mean levels of day 5 inhibin B were 747 pg/ml (all patients); cancelled cycles only had 67 pg/ml whereas patients with OHSS had 1572 pg/ml (Table IV) . 
Diagnostic predictive accuracy of various hormones at day 5
Multiple regression and multiple logistic regression models using the hormones measured at day 5 (inhibin A, inhibin B and estradiol), basal day 3 FSH, the patient's age and length of infertility as the independent variables were analysed with regard to ovarian response in terms of the numbers of mature oocytes retrieved. Only the day 5 inhibin B level predicted the ovarian response in terms of the number of mature oocytes (odds ratio ϭ 0.9899, 95% CI: 0.98-0.99, P ϭ 0.047) compared with day 5 inhibin A (P ϭ 0.4, not significant) and day 5 estradiol (P ϭ 0.8, not significant). The distribution of the day 5 inhibin B levels for the patients is shown in Figure 1 . The 25% percentile cut-off point was 373 pg/ml. To analyse further the diagnostic accuracy of different hormones to discriminate between poor and normal ovarian response as indicated by the number of mature oocytes, AUC ROC values were determined by ROC analysis for each hormone. The ovarian response threshold selected (i.e. less than 8 mature oocytes ϭ a poor ovarian response) was chosen as it defines 25% of the study population. Figure 2 shows the calculated AUC ROC for the best predictive variable of poor ovarian response, day 5 inhibin B. Day 5 inhibin B had the highest AUC ROC (0.955 Ϯ 0.03; 95% CI: 0.861-0.992) and was able to predict the poor ovarian response with 95.5% accuracy (Figure 2 ). This ROC analysis provides information on the likely inflexion point which can be used to discriminate between patients likely to respond adequately to treatment from poor or non-responders. Using the value of 373 for inhibin B (rounded up to 400) pg/ml as the cut-off point, day 5 inhibin B gave the highest prediction of 30.1 positive likelihood ratio, 92.9% sensitivity, 95.0% specificity, 86.7% positive predictive value and 97.4% negative predictive value for ovarian response for the study population. Using a threshold of less than 7 oocytes (n ϭ 14 patients), day 5 inhibin B predicted ovarian response in terms of retrieved mature oocytes (odds ratio 1.015, 95% CI 1.002-1.0304, P ϭ 0.04) with AUC ROC of 0.964 and a specificity of 93%. Using a threshold of less than 6 oocytes (n ϭ 11 patients), day 5 inhibin B predicted ovarian response in terms of retrieved mature oocytes (odds ratio 1.028, 95% CI 1.006-1.056, P ϭ 0.04) with ROC AUC 0.987 and a specificity of 91%. Too few patients (n ϭ 6) produced less than 5 oocytes for meaningful statistical analysis.
The diagnostic accuracy of the different hormone variables to discriminate between ongoing pregnancy and birth cases and non-ongoing pregnant IVF cases was also analysed using the ROC plot and the best predictor was again the day 5 inhibin B (0.699 ϩ 0.07; 95% CI: 0.558-0.841, P ϭ 0.002).
Following the above analysis, the patients were divided into two groups: low day 5 inhibin (Ͻ400 pg/ml, n ϭ 16; group 1) and high day 5 inhibin (Ͼ400 pg/ml, n ϭ 38; group 2). There were no differences (data not shown) in the age, BMI, type of infertility, cause of infertility, duration of infertility, duration of stimulation and dose of gonadotrophins used between group 1 and group 2. Further, pre-treatment hormone levels (FSH, E 2 and inhibin B) were similar (data not shown) between the groups whereas day 5 inhibin B per follicle (ജ14 mm) was (53 pg/ml, 95% CI: 44-63) in group 1,~2.5-fold less than in group 2 (129 pg/ml, 95% CI: 114-144). Women in group 1 had lower (P Ͻ 0.0001) mean day 5 inhibin A and B serum levels. Day 5 serum estradiol levels were directly proportional (P Ͻ 0.0001) to day 5 inhibin B levels in the two groups. There was a strong association between serum day 5 inhibin B concentration with the dose of gonadotrophin administered (P ϭ 0.003), numbers of follicles at day 5, mature follicles Ͼ14 mm, mature oocytes (P ϭ 0.0001), fertilized oocytes (P ϭ 0.03), developed embryos (P ϭ 0.03) and transferred embryos (P ϭ 0.03). Additionally, it was noted that all the cancelled cycles (4/54 cases) were in the low day 5 inhibin B group (Table V) .
All the ongoing pregnancies and births (n ϭ 9) were in the day 5 inhibin B Ͼ400 pg/ml group (live-birth rate/cycle 21%), while the low inhibin group had only one pregnancy, which resulted in early miscarriage (live-birth rate 0%). The difference in pregnancies between the two groups did not reach significance (P ϭ 0.09), probably due to the small numbers of patients. When the total cases (n ϭ 54) were divided into groups of pregnant (n ϭ 10) and non-pregnant (n ϭ 40) cases, there were no differences in terms of patient profiles and outcome parameters. However, the mean day 5 inhibin B (946; 95% CI: 699-1194) in the ongoing pregnant group was higher than the day 5 inhibin B (662; 95% CI: 526-799) in the nonpregnant group (P ϭ 0.07, not significant).
Discussion
Poor responses to ovarian stimulation in normogonadotrophic, normogonadal women have been reported (Farhi et al., 1997) . Although several studies, which have been the subject of recent comprehensive reviews (Broekmans et al., 1998; Sharara et al., 1998) , have attempted to develop tests for predicting ovarian reserve; these tests have limited value (Galtier-Dereure et al., 1996) and doubts remain about their accuracy and interpretation (Barnhart and Osheroff, 1999) . Thus the clinician is often left puzzled by the discordant responses seen in this group of patients.
Basal FSH levels in the current study, measured in the previous menstrual cycle, were normal at Ͻ8.5 IU/l and were inversely proportional (P Ͻ 0.002) to day 5 inhibin B levels in the treatment cycle. These FSH data confirm the findings of earlier studies (Cahill et al., 1994; Fawzy et al., 1997) .
It has been suggested that inhibin B, a granulosa cell product, may be more sensitive to the stimulus of FSH than inhibin A and estradiol in the early phase of the menstrual cycle (Burger et al., 1998) or stimulated IVF cycle (Lockwood et al., 1996; Anderson et al., 1998) . It has also been demonstrated that a decrease in inhibin B secretion is an early marker of declining reproductive potential which is linked to both quantitative and qualitative changes in oocytes (Seki et al., 1997; Seifer et al., 1997 Seifer et al., , 1999 Welt et al., 1999a) . Studies in the mouse and in the human have also shown that inhibin B is an indicator of the best quality follicles, which were higher in number in subjects who became pregnant (Smitz and Cortvrindt, 1998; Hall et al., 1999) .
Although previous studies have demonstrated that inhibin B can serve as the earliest index of FSH-dependent growth of antral follicles and as a direct measure of ovarian reserve (Lockwood et al., 1996; Welt et al., 1997 Welt et al., , 1999b Danforth et al., 1998) , few reports have explored the relationship between serum inhibins, follicle number, and IVF treatment outcome during the early phase of gonadotrophin stimulation (Dokras et al., 2000; Eldar-Geva et al., 2000; Peñarrubia et al., 2000) . Furthermore, to date, all investigations that have examined inhibin B as a predictor of ovarian stimulation (Siefer et al., 1997 (Siefer et al., , 1999 Hofmann et al., 1998; Corson et al., 1999; Hall et al., 1999; Tinkanen et al., 1999; Creus et al., 2000; Dokras et al., 2000; Dzik et al., 2000; Peñarrubia et al., 2000; Ravhon et al., 2000) , with one exception (Eldar-Geva et al., 2000) , have been retrospective analyses.
In this the first prospective, assessor-blind study, we have established the value of serum day 5 inhibin B of a stimulated IVF treatment cycle as a predictor of all relevant outcomes in apparently normal women. The strict inclusion and exclusion criteria ensured that the women recruited had normal ovaries by ultrasound appearance, normal levels of gonadotrophins, were Ͻ39 years of age, and had no previous exposure to gonadotrophin stimulation. Only patients with unexplained or tubal infertility were chosen as there is no difference in pregnancy rates between these two categories in this Unit (Fawzy et al., 1997) or in a recent published report (Human Fertilisation and Embryology Authority, 2000) .
Multivariate logistic regression and ROC analyses of the results were used to discriminate between poor/normal ovarian response and pregnant/non-pregnant cycles. Our results, which are in agreement with those reported by others (Eldar-Geva et al., 2000; Peñarrubia et al., 2000) , indicate that serum day 5 inhibin B has the highest predictive power to discriminate between poor and normal ovarian response.
The most striking finding of the predictive power of the day 5 inhibin B levels relates to the number of pregnancies in these age-matched groups. Previous studies suggested that age is a strong predictor of pregnancy rate (Commenges-Ducos et al., 1998; Sharif et al., 1998; Hall et al., 1999 , Fabregues et al., 2000 , although other reports contradict this finding (Toner et al., 1991; Toner, 1993; Check et al., 1994) . In our study, there was only one pregnancy, which ended in Data are presented as mean Ϯ SD. Group 1 includes patients with day 5 inhibin B Ͻ400 pg/ml and group 2 includes patients with day 5 inhibin B Ͼ400 pg/ml. NS ϭ not significant. miscarriage, in the low day 5 inhibin B (Ͻ400 pg/ml) group compared with nine pregnancies resulting in one miscarriage and nine live births (eight singleton and one twin; live-birth rate/cycle 21%) in the high day 5 inhibin group. Peñarrubia et al. (2000) stated that day 5 inhibin B, inhibin A and estradiol had similar, but poor, predictive properties on pregnancy outcome while Eldar-Geva et al. (2000) failed to report on the pregnancy outcome, in their study. In the present study, day 5 inhibin B alone was also the best predictor of the birth rate out of all the hormones studied alone or combined with age and duration of infertility. However, this result should be interpreted with caution because of the small number of cases. Poor ovarian response, in terms of low numbers of mature follicles (Ͼ14 mm diameter) and mature oocytes retrieved, is usually associated with poor pregnancy rates and poor oocyte quality (Keay et al., 1997) . Peñarrubia et al. (2000) reported that a cut-off of day 5 inhibin B of 141 pg/ml gave a predictive efficiency (product of sensitivity and specificity) of 91.03% for cancellation. However, their cancellation rate (25%) was high compared with the internationally published rate of 8.6% (Human Fertilisation and Embryology Authority, 2000; Society for Assisted Reproductive Technology/American Society for Reproductive Medicine, 2000) . In the current study, the mean day 5 inhibin was 67 pg/ml in the four (7.5%) cycles cancelled because of poor ovarian response.
In contrast, the mean day 5 inhibin B level was 1572 pg/ml in the six patients who suffered mild/moderate OHSS (more than 20 oocytes). In agreement with this finding, one study (Enskog et al., 2000) reported that the elevation of serum inhibin B 3 days prior to oocyte retrieval was greater in patients who later developed OHSS. Concerns have been expressed about the value of plasma estradiol measurements in predicting OHSS, a condition which is apparently exacerbated by the use of recombinant FSH preparations which lead to a reduction of the amount of estradiol secreted per follicle (Devroey et al., 1994; Lockwood et al., 1996; Jacob et al., 1998; Fawzy et al., 2001) . Consequently, day 5 inhibin B measurements may be a useful tool in predicting and monitoring OHSS. However, further studies with a larger number of patients are needed to support these findings.
The results of the present study suggest that a serum day 5 inhibin B level Ͻ100 pg/ml may be an indication for cancellation of that cycle. Conversely, patients with a high day 5 inhibin B level (Ͼ1000 pg/ml) may benefit from a reduction in the gonadotrophin dose and closer follow-up during stimulation. However, cut-off values should act only as guidelines and should not exclude patients from treatment, but should allow for proper counselling and better planning of the most appropriate treatment. For example, patients with diminished ovarian reserve with low serum day 5 inhibin B level (Ͻ400 pg/ml) may benefit from stimulation with a higher dose of gonadotrophin or possibly a modification in GnRH agonist administration. No test of ovarian reserve is likely to be precise enough to merit total reliance on the results, and all relevant findings such as patient history, scan results and patient's age should be taken into account.
With respect to estradiol, the levels of this hormone in the early follicular phase have been reported to be highly predictive of successful ovulation stimulation and pregnancy outcome (Phelps et al., 1998; Khalaf et al., 2000) but these authors did not report on basal day 3 hormones or inhibin(s). We found the predictive value of day 5 estradiol to be inferior to day 5 inhibin B with respect to both ovarian stimulation and pregnancy outcome.
In conclusion, serum day 5 inhibin B measured during gonadotrophin stimulation was a better marker for oocyte maturity and pregnancy rate than the other day 5 hormones such as estradiol and inhibin A. It is also a useful predictor of poor-response and for the monitoring of over-response. This information may be helpful to counsel patients who would otherwise expect a different outcome. Our study and previous studies provide further evidence that stimulated serum inhibin B measurement in the early follicular cycle, either alone or in combination with other ovarian predictive measures, may be an essential part of the future management of patients undergoing ovarian stimulation. A large prospective multicentre study is needed to confirm our findings and to set a cut-off point of inhibin B for either discontinuation or monitoring of the stimulation cycle for poor or over-response.
